A Low-Titer Inhibitor and a Ten-Year-Old's Central Line: Emicizumab or One More Try at Tolerance
A boy's low-titer factor VIII inhibitor could plausibly still be eradicated with immune tolerance induction — but that path runs through the exact kind of daily infusion burden his family has already spent two years trying to escape.
J.M., a 10-year-old boy with severe hemophilia A, developed a factor VIII inhibitor two years ago, low-titer at 2.4 Bethesda units, discovered when his usual prophylactic factor VIII dose stopped controlling a recurrent knee bleed the way it always had. He has been on immune tolerance induction since then — daily high-dose factor VIII infusions through a surgically placed central line, the standard approach aimed at retraining his immune system to stop recognizing the factor as foreign. His mother, who manages the infusions, brought up at today's visit, unprompted, how much of the family's daily routine has been built around that line for over a year: school drop-off timed around infusion windows, a rotating schedule of who flushes it on weekends, two line infections requiring hospitalization along the way.
His titer has fallen from 2.4 to 0.6 Bethesda units over fourteen months of ITI — real, measurable progress toward the tolerance the protocol is designed to achieve, though not yet the negative titer that would mark success. Emicizumab, a bispecific antibody that bridges factor IXa and factor Xa to mimic activated factor VIII's function, would let him stop the daily infusions and switch to a subcutaneous injection every one to four weeks regardless of his inhibitor status — HAVEN 2, the arm of that trial program run specifically in children under twelve with inhibitors rather than the adolescents and adults HAVEN 1 enrolled, showed a dramatic drop in treated bleeds in patients his own age. It would not, however, eradicate the inhibitor itself, and any breakthrough bleed on emicizumab would need treatment with a bypassing agent rather than factor VIII, with an explicit, labeled warning against combining it with activated prothrombin complex concentrate given a documented thrombotic microangiopathy risk when the two are used together.
His breakthrough knee bleed six months ago, while on ITI, was managed with recombinant factor VIIa rather than aPCC specifically because his care team had already begun planning for the possibility of an eventual switch to emicizumab — a small, forward-looking decision that is now paying off as tonight's conversation unfolds, since it means no aPCC exposure history complicates whichever path the family chooses.
At the fourteen-month mark, deciding whether to keep going
His titer has come down from 2.4 to 0.6 over fourteen months — that's real progress toward eradication, and low-titer inhibitors like his have the best published ITI success rates of any category. Stopping now, this close, would mean walking away from a trajectory that's actually working, not one that's stalled.
I don't dispute the titer trend, but I want the family's actual reported experience treated as a real clinical input, not background noise around the lab value. Two hospitalizations for line infections in fourteen months, and his mother telling us directly today how much of their daily life is built around this schedule — that's an already-occurring cost, not a hypothetical one we're weighing against a hypothetical benefit.
Titer progress is real, but 'it's working' and 'it's sustainable for this family' are two different claims, and only one of them has been getting worse, not better, over the same fourteen months.
I think both of those concerns point to the same fix: a bounded trial, not an open-ended one. Three more months, with an explicit titer target and an explicit agreement that a third line complication of any kind ends ITI regardless of where the titer sits. That gives the trend a real chance to finish, and gives the family a concrete end date instead of an indefinite one — which, said directly, is likely a real part of what's exhausting them.
If he crosses to a negative titer in that window, ITI has done its job. If he doesn't, or the line fails again, emicizumab is the plan on day one of month four, no further debate needed at that point.
Agreed with the family present: a three-month bounded ITI trial, explicit titer target of undetectable, explicit line-complication limit of one further event before automatic transition. Mother visibly relieved at having a fixed date rather than an open-ended commitment, regardless of which way it resolves.
ITI is declared successful, the central line is removed, and he returns to standard-dose factor VIII prophylaxis without an inhibitor.
Emicizumab starts immediately, with bypassing-agent-only bleed management and an explicit aPCC-avoidance note added to his emergency action plan.